Insider Trading Alert - ABAX, TRNS And EPD Traded By Insiders

Yesterday, Feb. 11, 2016, 59 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $190.35 to $8,939,553.07.

Highlighted Stocks Traded by Insiders:

Abaxis (ABAX) - FREE Research Report

Altman Vernon E, who is Director at Abaxis, bought 303 shares at $39.87 on Feb. 11, 2016. Following this transaction, the Director owned 16,303 shares meaning that the stake was boosted by 1.89% with the 303-share transaction.

The shares most recently traded at $39.12, down $0.75, or 1.93% since the insider transaction. Historical insider transactions for Abaxis go as follows:

  • 4-Week # shares sold: 560
  • 12-Week # shares sold: 560
  • 24-Week # shares sold: 560

The average volume for Abaxis has been 200,900 shares per day over the past 30 days. Abaxis has a market cap of $886.9 million and is part of the health care sector and health services industry. Shares are down 30.54% year-to-date as of the close of trading on Thursday.

Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The stock currently has a dividend yield of 1.12%. The company has a P/E ratio of 33.5. Currently, there is 1 analyst who rates Abaxis a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ABAX - FREE

TheStreet Quant Ratings rates Abaxis as a hold. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and a generally disappointing performance in the stock itself. Get the full Abaxis Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Transcat (TRNS) - FREE Research Report

Sassano Carl E, who is Director at Transcat, sold 5,000 shares at $9.69 on Feb. 11, 2016. Following this transaction, the Director owned 96,575 shares meaning that the stake was reduced by 4.92% with the 5,000-share transaction.

The shares most recently traded at $9.50, down $0.19, or 1.95% since the insider transaction. Historical insider transactions for Transcat go as follows:

  • 4-Week # shares bought: 6,000
  • 4-Week # shares sold: 6,000
  • 12-Week # shares bought: 6,000
  • 12-Week # shares sold: 6,000
  • 24-Week # shares bought: 6,000
  • 24-Week # shares sold: 6,000

The average volume for Transcat has been 9,200 shares per day over the past 30 days. Transcat has a market cap of $64.1 million and is part of the technology sector and electronics industry. Shares are down 6.64% year-to-date as of the close of trading on Wednesday.

Transcat, Inc. provides calibration, repair, inspection, and compliance services in the United States, Canada, and internationally. It operates in two segments, Distribution and Service. The Service segment offers calibration service on new and used instruments and repair services. The company has a P/E ratio of 14.7. Currently, there are no analysts who rate Transcat a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TRNS - FREE

TheStreet Quant Ratings rates Transcat as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and good cash flow from operations. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Transcat Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Enterprise Products Partners (EPD) - FREE Research Report

Montgomery William C, who is Director at Enterprise Products Partners, bought 10,000 shares at $19.69 on Feb. 11, 2016. Following this transaction, the Director owned 36,500 shares meaning that the stake was boosted by 37.74% with the 10,000-share transaction.

The shares most recently traded at $19.79, up $0.10, or 0.51% since the insider transaction. Historical insider transactions for Enterprise Products Partners go as follows:

  • 4-Week # shares bought: 2,500
  • 4-Week # shares sold: 12,000
  • 12-Week # shares bought: 140,975
  • 12-Week # shares sold: 12,000
  • 24-Week # shares bought: 147,375
  • 24-Week # shares sold: 12,000

The average volume for Enterprise Products Partners has been 8.2 million shares per day over the past 30 days. Enterprise Products Partners has a market cap of $41.7 billion and is part of the basic materials sector and energy industry. Shares are down 18.92% year-to-date as of the close of trading on Wednesday.

Enterprise Products Partners L.P. provides midstream energy services to producers and consumers of natural gas, natural gas liquids (NGLs), crude oil, petrochemicals, and refined products in the United States and internationally. The stock currently has a dividend yield of 7.5%. The company has a P/E ratio of 16.5. Currently, there are 19 analysts who rate Enterprise Products Partners a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EPD - FREE

TheStreet Quant Ratings rates Enterprise Products Partners as a hold. The company's strengths can be seen in multiple areas, such as its increase in net income and notable return on equity. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk, a generally disappointing performance in the stock itself and weak operating cash flow. Get the full Enterprise Products Partners Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.